Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
We previously reported that sodium-glucose cotransporter 2 inhibitors (SGLT2i) improved the eGFR slope in patients with IgA nephropathy (IgAN), independently of proteinuria reduction. In this study, we compared the renal effects and associated clinical parameters of SGLT2i between IgAN and diabetic kidney disease (DKD) to explore potential differences in their underlying mechanisms.
Patients with available clinical data for at least six months before and after SGLT2i initiation were analyzed. The IgAN group included biopsy-proven cases, whereas the DKD group comprised patients with diabetes as the primary renal disease. Changes in clinical parameters—body weight (BW), urinary protein (uP), uric acid (UA), hemoglobin (Hgb), and eGFR—were evaluated at baseline, 3 months, and 6 months. The eGFR slope was calculated using linear regression from 3–10 serial eGFR values, and correlations between ΔeGFR slope and ΔBW, ΔuP, ΔUA, and ΔHgb were examined.
A total of 99 patients were included (IgAN: n=60; DKD: n=39). Mean age was 57.1±1.76 years in IgAN and 63.6±2.01 years in DKD, with lower baseline eGFR in DKD (39.9±4.53 vs. 49.4±2.73 mL/min/1.73m²). Baseline proteinuria was higher in DKD (2.59±0.41 vs. 1.29±0.14 g/gCr). BW tended to be higher in DKD.Treatment with ACE inhibitors or angiotensin rceptor blockers (ACE-I/ARB) was continued in 47 patients in the IgAN group and 39 patients in the DKD group. Over time, BW continuously decreased in both groups, whereas proteinuria transiently decreased at 3 months but increased again at 6 months in DKD. eGFR declined during the first 6 months, but eGFR slope significantly improved both in IgAN (from −3.47±0.56 to −0.78±0.48 mL/min/1.73m², p<0.001) and DKD (from −5.64±1.08 to −3.45±1.00, p=0.018). UA significantly decreased and Hgb significantly increased in both groups. The degree of improvement in eGFR slope did not differ between groups. BW reduction was greater in DKD, while the magnitude of proteinuria reduction was similar. UA reduction tended to be greater in IgAN, and Hgb increase was significantly greater in IgAN. Correlation analyses revealed no significant relationship between ΔuP or ΔBW and ΔeGFR slope. However, ΔUA showed a significant negative correlation with ΔeGFR slope in IgAN (p=0.010), whereas ΔHgb correlated positively with ΔeGFR slope in DKD (p=0.026). These findings suggest that, although the overall renal benefit of SGLT2i was comparable, the associated clinical patterns differed between diseases.
SGLT2i treatment improved eGFR slope similarly in IgAN and DKD, with consistent trends in metabolic and hematologic parameters. However, the principal factors associated with renal protection appear to differ depending on disease background, implying distinct mechanistic pathways in IgAN and DKD.
